CD8A and melanoma: Indeed, NK cells are essential for effective melanoma control in mice treated with the BRAF inhibitor PLX472021 and, in human paired-biopsy studies, treatment with BRAF-inhibitor increases tumor infiltration by cytotoxic CD8+ T cells.22 Here, we show that melanoma control by targeted therapy with PLX4720 requires an immunocompetent host and reveal that efficacy can be enhanced in the absence of sGSN.